Subcutaneous Treprostinil

DRUG2 trials

Sponsors

United Therapeutics, Guangzhou Institute of Respiratory Disease

Conditions

Chronic Lung Disease-Associated Pulmonary HypertensionHeart FailureLung TransplantationPulmonary Arterial HypertensionPulmonary Hypertension

Phase 4

An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension

WithdrawnNCT02882126

United TherapeuticsPulmonary Arterial Hypertension

Start: 2017-06-30End: 2021-06-30Updated: 2017-05-09

Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm Retrospective Study

CompletedNCT06605326

Guangzhou Institute of Respiratory DiseaseChronic Lung Disease-Associated Pulmonary Hypertension, Heart Failure, Lung Transplantation +2

Start: 2015-01-01End: 2024-09-01Updated: 2024-09-23